Edition:
United States

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

11.54USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$11.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,825
52-wk High
$18.93
52-wk Low
$10.92

Latest Key Developments (Source: Significant Developments)

Spring Bank Pharmaceuticals Says Net Loss For Three Months Ended March 31, 2018 Was $4.9 Mln, Or $0.37 Per Share
Friday, 27 Apr 2018 08:01am EDT 

April 27 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS INC - NET LOSS FOR THREE MONTHS ENDED MARCH 31, 2018 WAS $4.9 MILLION, OR $0.37 PER SHARE.SPRING BANK PHARMACEUTICALS - ANTICIPATES THAT EXISTING CASH, CASH EQUIVALENTS WILL ENABLE CO TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS INTO Q4 2019.SPRING BANK PHARMA - ANTICIPATES THAT EXISTING CASH, CASH EQUIVALENTS WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR.  Full Article

Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11
Tuesday, 20 Feb 2018 04:30pm EST 

Feb 20 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS.Q4 LOSS PER SHARE $0.11.SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2019.SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR.SPRING BANK PHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $50.6 MILLION AS OF DEC 31, 2017, COMPARED TO $25.5 MILLION AS OF DEC 31, 2016.  Full Article

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Wednesday, 15 Nov 2017 04:30pm EST 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Spring Bank Pharmaceuticals - Q3 loss per share $0.85
Tuesday, 31 Oct 2017 06:45am EDT 

Oct 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports third quarter 2017 financial and operational results.Q3 loss per share $0.85.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals - top-line results from second inarigivir monotherapy dosing cohort of achieve trial will be released in Q4 2017​.Spring Bank Pharmaceuticals - expects existing cash, cash equivalents, marketable securities will enable co to fund expenses, capex through 2019-end.Spring Bank - expects cash, cash equivalents, marketable securities will not be enough to fund development of inarigivir beyond Phase 2 achieve trial​.  Full Article

BVF Partners reports 5.1 pct passive stake in Spring Bank Pharmaceuticals as of Aug. 3
Friday, 11 Aug 2017 05:35pm EDT 

Aug 11 (Reuters) - BVF Partners L.P: :BVF Partners L.P reports 5.1 percent passive stake in spring bank pharmaceuticals inc as of august 3, 2017 - SEC filing‍​.  Full Article

Spring Bank Pharmaceuticals posts Q2 loss per share $0.93
Monday, 31 Jul 2017 04:15pm EDT 

July 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports second quarter 2017 financial and operational results.Q2 loss per share $0.93.Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals-sees existing cash,among others to not be sufficient for additional development of sb 9200 beyond Phase 2 achieve clinical trial.Spring Bank Pharmaceuticals-anticipates existing cash,among others will enable it to fund operating expenses, cap ex requirements through end of 2019.Spring Bank Pharmaceuticals-plans to report top-line results from second monotherapy dosing cohort of achieve global Phase 2 trial of SB 9200 in Q4.  Full Article

Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200​
Monday, 10 Jul 2017 08:30am EDT 

July 10 (Reuters) - Gilead Sciences Inc :Spring Bank Pharmaceuticals Inc - ‍announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining SB 9200​.Spring Bank Pharmaceuticals - ‍under terms of clinical trial supply, collaboration agreement, Gilead will lead Phase 2 trial with input from spring bank​.  Full Article

Spring Bank Pharma prices $37.5 mln public offering of common stock
Thursday, 22 Jun 2017 09:00am EDT 

June 22 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring bank pharmaceuticals prices $37.5 million public offering of common stock.Says public offering of 2.88 million common shares priced at $13.00per share.  Full Article

Spring Bank Pharma announces proposed public offering of common stock
Wednesday, 21 Jun 2017 04:00pm EDT 

June 21 (Reuters) - Spring Bank Pharmaceuticals Inc ::Spring Bank Pharmaceuticals announces proposed public offering of common stock.Intends to use net proceeds from offering for continued development of its product candidates.  Full Article

Spring Bank Pharma provides positive mid-stage data on Hep B drug
Tuesday, 23 May 2017 04:00pm EDT 

May 23 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring bank pharmaceuticals announces top-line results from the initial cohort of the phase 2a segment of the achieve trial, a global phase 2 clinical trial for chronic hepatitis b virus (hbv).Spring bank - sb 9200 shows favorable safety profile and antiviral activity against hbv dna and hbsag with initial low dose monotherapy of 25mg.Spring bank pharmaceuticals inc - overall safety profile of sb 9200 was favorable, and over 12-week study, no serious adverse events were observed.  Full Article

BRIEF-Spring Bank Pharma Appoints Timothy Clackson To Board

* SPRING BANK PHARMACEUTICALS APPOINTS TIMOTHY CLACKSON, PH.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: